Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Aviragen Therapeutics Inc (NASDAQ:AVIR)

During the Trading Day
0.5963 +0.0263 / +4.61%
As of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
0.595 -0.0013 / -0.22%
Volume: 4.1K
Health Technology

Company Description

Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.

Contact Information

Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Alpharetta Georgia 30009
P:(678) 221-3343
Investor Relations:



Mutual fund holders6.81%
Other institutional28.76%
Individual stakeholders0.96%

Top Executives

Joseph M. PattiPresident, CEO & Executive Director
Mark P. ColonneseChief Financial Officer & Executive Vice President
Anna Novotney-BarryVice President-Clinical Development
John H. VernachioVice President-Preclinical Development
Jonas NiauraVice President-Corporate Development & Strategy